Structural insights into the inhibition of cytosolic 5′-nucleotidase ii (cN-II) by ribonucleoside 5′-monophosphate analogues

PLoS Computational Biology

Volumn 7, Issue 12, 2011, Pages

  Gallier, Franck ^a   Lallemand, Perrine ^b   Meurillon, Maïa ^a   Jordheim, Lars P ^c   Dumontet, Charles ^c   Périgaud, Christian ^a   Lionne, Corinne ^b   Peyrottes, Suzanne ^a   Chaloin, Laurent ^b  

^a UNIVERSITÉ DE MONTPELLIER   (France)

^b University of Montpellier I and II   (France)

^c UNIVERSITÉ LYON 1   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMICAL MODIFICATION; PATIENT TREATMENT; VAN DER WAALS FORCES;

CYTOSOLIC; CYTOTOXIC; DEPHOSPHORYLATIONS; MONOPHOSPHATES; NUCLEOSIDE ANALOGS; NUCLEOTIDE POOLS; PHOSPHONATES; PHYSIOLOGICAL FUNCTIONS; RIBONUCLEOSIDES; STRUCTURAL INSIGHTS;

LIGANDS;

5' NUCLEOTIDASE; CYTOSOLIC 5' NUCLEOTIDASE II; ENZYME INHIBITOR; INOSINE PHOSPHATE; NUCLEOTIDASE; ORGANOPHOSPHATE; PHOSPHONIC ACID DERIVATIVE; PURINE DERIVATIVE; PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG; RIBONUCLEOTIDE;

ARTICLE; BINDING AFFINITY; COMPUTER MODEL; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SUBSTRATE; HYDROPHOBICITY; IN VITRO STUDY; LINKAGE ANALYSIS; MOLECULAR DOCKING; MOLECULAR INTERACTION; OUTCOME ASSESSMENT; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; BINDING SITE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; ENZYME SPECIFICITY; HYDROLYSIS; METABOLISM;

5'-NUCLEOTIDASE; BINDING SITES; HYDROLYSIS; INOSINE MONOPHOSPHATE; MODELS, MOLECULAR; RIBONUCLEOTIDES; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY;

EID: 84855264170     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.1002295     Document Type: Article

References (50)

1. Reis MJ, (1934) Nucleotidase and its relation to the deamination of nucleotides in the heart and the muscles. Bull Soc Chim Biol 16: 385-399.
2. Hunsucker SA, Mitchell BS, Spychala J, (2005) The 5′-nucleotidases as regulators of nucleotide and drug metabolism. Pharmacol Ther 107: 1-30.
3. Bianchi V, Spychala J, (2003) Mammalian 5′-nucleotidases. J Biol Chem 278: 46195-46198.
4. Bretonnet AS, Jordheim LP, Dumontet C, Lancelin JM, (2005) Regulation and activity of cytosolic 5′-nucleotidase II. A bifunctional allosteric enzyme of the Haloacid Dehalogenase superfamily involved in cellular metabolism. FEBS Lett 579: 3363-3368.
5. Worku Y, Newby AC, (1982) Nucleoside exchange catalysed by the cytoplasmic 5′-nucleotidase. Biochem J 205: 503-510.
6. Baiocchi C, Pesi R, Camici M, Itoh R, Grazi Tozzi M, (1996) Mechanism of the reaction catalysed by cytosolic 5′-nucleotidase/phosphotransferase: formation of a phosphorylated intermediate. Biochem J 317: 797-801.
7. Zimmermann H, (1992) 5′-Nucleotidase: molecular structure and functional aspects. Biochem J 285: 345-365.
8. Spychala J, Madrid-Marina V, Fox IH, (1988) High Km soluble 5′-nucleotidase from human placenta. Properties and allosteric regulation by IMP and ATP. J Biol Chem 263: 18759-18765.
9. Pesi R, Baiocchi C, Tozzi MG, Camici M, (1996) Synergistic action of ADP and 2,3-bisphosphoglycerate on the modulation of cytosolic 5′-nucleotidase. Biochim Biophys Acta 1294: 191-194.
10. Marques AF, Teixeira NA, Gambaretto C, Sillero A, Sillero MA, (1998) IMP-GMP 5′-nucleotidase from rat brain: activation by polyphosphates. J Neurochem 71: 1241-1250.
11. Wallden K, Nordlund P, (2011) Structural Basis for the Allosteric Regulation and Substrate Recognition of Human Cytosolic 5′-Nucleotidase II. J Mol Biol 408: 684-696.
12. Spychala J, (2000) Tumor-promoting functions of adenosine. Pharmacol Ther 87: 161-173.
13. Amici A, Magni G, (2002) Human erythrocyte pyrimidine 5′-nucleotidase, PN-I. Arch Biochem Biophys 397: 184-190.
14. Mazzon C, Rampazzo C, Scaini MC, Gallinaro L, Karlsson A, et al. (2003) Cytosolic and mitochondrial deoxyribonucleotidases: activity with substrate analogs, inhibitors and implications for therapy. Biochem Pharmacol 66: 471-479.
15. Galmarini CM, Thomas X, Calvo F, Rousselot P, Rabilloud M, et al. (2002) In vivo mechanisms of resistance to cytarabine in acute myeloid leukaemia. Br J Haematol 117: 860-868.
16. Mitra AK, Crews K, Pounds S, Cao X, Feldberg T, et al. (2011) Genetic variants in NT5C2 are associated with its expression and cytarabine sensitivity in HapMap cell lines and in AML patients. J Pharmacol Exp Ther 339: 9-23.
17. Suzuki K, Sugawara T, Oyake T, Uchiyama T, Aoki Y, et al. (2007) Clinical significance of high-Km 5′-nucleotidase (cN-II) mRNA expression in high-risk myelodysplastic syndrome. Leuk Res 31: 1343-1349.
18. Albertioni F, Karlsson K, Juliusson G, Lofti K, (2007) Relationship of 5′-nucleotidase and deoxynucleoside kinase activity to the clinical activity of cladribine and fludarabine. Proc of the 98th Annual Meeting of the Amer Assoc Cancer Res, Los Angeles, CA AACR; 2007 Abstract nr 941.
19. Careddu MG, Allegrini S, Pesi R, Camici M, Garcia-Gil M, et al. (2008) Knockdown of cytosolic 5′-nucleotidase II (cN-II) reveals that its activity is essential for survival in astrocytoma cells. Biochim Biophys Acta 1783: 1529-1535.
20. Moitessier N, Englebienne P, Lee D, Lawandi J, Corbeil CR, (2008) Towards the development of universal, fast and highly accurate docking/scoring methods: a long way to go. Br J Pharmacol 153 (Suppl 1): S7-26.
21. Sousa SF, Fernandes PA, Ramos MJ, (2006) Protein-ligand docking: current status and future challenges. Proteins 65: 15-26.
22. Friesner RA, Murphy RB, Repasky MP, Frye LL, Greenwood JR, et al. (2006) Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J Med Chem 49: 6177-6196.
23. Warren GL, Andrews CW, Capelli AM, Clarke B, LaLonde J, et al. (2006) A critical assessment of docking programs and scoring functions. J Med Chem 49: 5912-5931.
24. Sherman W, Beard HS, Farid R, (2006) Use of an induced fit receptor structure in virtual screening. Chem Biol Drug Des 67: 83-84.
25. Gallier F, Peyrottes S, Perigaud C, (2007) Ex-chiral-pool synthesis of beta-hydroxyphosphonate nucleoside analogues. Eur J Org Chem 6: 925-933.
26. Rinaldo-Matthis A, Rampazzo C, Reichard P, Bianchi V, Nordlund P, (2002) Crystal structure of a human mitochondrial deoxyribonucleotidase. Nat Struct Biol 9: 779-787.
27. Jordheim LP, Cros E, Galmarini CM, Dumontet C, Bretonnet AS, et al. (2006) F-ara-AMP is a substrate of cytoplasmic 5′-nucleotidase II (cN-II): HPLC and NMR studies of enzymatic dephosphorylation. Nucleosides Nucleotides Nucleic Acids 25: 289-297.
28. Kochanowski N, Blanchard F, Cacan R, Chirat F, Guedon E, et al. (2006) Intracellular nucleotide and nucleotide sugar contents of cultured CHO cells determined by a fast, sensitive, and high-resolution ion-pair RP-HPLC. Anal Biochem 348: 243-251.
29. Ng M, Blaschke TF, Arias AA, Zare RN, (1992) Analysis of free intracellular nucleotides using high-performance capillary electrophoresis. Anal Chem 64: 1682-1684.
30. Traut TW, (1994) Physiological concentrations of purines and pyrimidines. Mol Cell Biochem 140: 1-22.
31. Musmuca I, Caroli A, Mai A, Kaushik-Basu N, Arora P, et al. (2010) Combining 3-D quantitative structure-activity relationship with ligand based and structure based alignment procedures for in silico screening of new hepatitis C virus NS5B polymerase inhibitors. J Chem Inf Model 50: 662-676.
32. Didziapetris R, Dapkunas J, Sazonovas A, Japertas P, (2010) Trainable structure-activity relationship model for virtual screening of CYP3A4 inhibition. J Comput Aided Mol Des 24: 891-906.
33. Baqi Y, Lee SY, Iqbal J, Ripphausen P, Lehr A, et al. (2010) Development of potent and selective inhibitors of ecto-5′-nucleotidase based on an anthraquinone scaffold. J Med Chem 53: 2076-2086.
34. Baqi Y, Weyler S, Iqbal J, Zimmermann H, Muller CE, (2009) Structure-activity relationships of anthraquinone derivatives derived from bromaminic acid as inhibitors of ectonucleoside triphosphate diphosphohydrolases (E-NTPDases). Purinergic Signal 5: 91-106.
35. Peyrottes S, Gallier F, Bejaud J, Perigaud C, (2006) Use of microwave irradiation for sugar and nucleoside phosphonates synthesis. Tetrahedron Letters 47: 7719-7721.
36. Meurillon M, Gallier F, Peyrottes S, Perigaud C, (2009) Developing an efficient route to the synthesis of nucleoside 1-alkynylphosphonates. Tetrahedron 65: 6039-6046.
37. Gallier F, Alexandre JAC, El Amri C, Deville-Bonne D, Peyrottes S, et al. (2011) 5′,6′-Nucleoside Phosphonate Analogues Architecture: Synthesis and Comparative Evaluation towards Metabolic Enzymes. ChemMedChem 6: 1094-1106.
38. Huang H, Chopra R, Verdine GL, Harrison SC, (1998) Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. Science 282: 1669-1675.
39. Painter GR, Aulabaugh AE, Andrews CW, (1993) A comparison of the conformations of the 5′-triphosphates of zidovudine (AZT) and thymidine bound to HIV-1 reverse transcriptase. Biochem Biophys Res Commun 191: 1166-1171.
40. Saran A, Perahia D, Pullman B, (1973) Molecular orbital calculations on the conformation of nucleic acids and their constituents. VII. Conformation of the sugar ring in β-nucleosides: the pseudorotational representation. Theoret chim Acta (Berl) 30: 31-44.
41. Wallden K, Stenmark P, Nyman T, Flodin S, Graslund S, et al. (2007) Crystal structure of human cytosolic 5′-nucleotidase II: insights into allosteric regulation and substrate recognition. J Biol Chem 282: 17828-17836.
42. Brooks BR, Brooks CL 3rd, Mackerell AD Jr, Nilsson L, Petrella RJ, et al. (2009) CHARMM: the biomolecular simulation program. J Comput Chem 30: 1545-1614.
43. MacKerell AD Jr, Banavali N, Foloppe N, (2000) Development and current status of the CHARMM force field for nucleic acids. Biopolymers 56: 257-265.
44. Zang R, Muller HJ, Kielbassa K, Marks F, Gschwendt M, (1994) Partial purification of a type eta protein kinase C from murine brain: separation from other protein kinase C isoenzymes and characterization. Biochem J 304: 641-647.
45. Gasteiger J, Marsili M, (1980) Iterative partial equalization of orbital electronegativity- a rapid access to atomic charges. Tetrahedron 36: 3219-3228.
46. DeLano WL, (2008) The PyMOL Molecular Graphics System DeLano Scientific LLC, Palo Alto, CA. http://www.pymol.org.
47. Humphrey W, Dalke A, Schulten K, (1996) VMD: visual molecular dynamics. J Mol Graph 14: 33-38 27-38.
48. Wallace AC, Laskowski RA, Thornton JM, (1995) LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein Eng 8: 127-134.
49. McDonald IK, Thornton JM, (1994) Satisfying hydrogen bonding potential in proteins. J Mol Biol 238: 777-793.
50. Spychala J, Chen V, Oka J, Mitchell BS, (1999) ATP and phosphate reciprocally affect subunit association of human recombinant High Km 5′-nucleotidase. Role for the C-terminal polyglutamic acid tract in subunit association and catalytic activity. Eur J Biochem 259: 851-858.